PMID- 24472266
OWN - NLM
STAT- MEDLINE
DCOM- 20140929
LR  - 20151119
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 17
IP  - 1
DP  - 2014 Jan
TI  - Celecoxib, a selective cyclooxygenase-2 inhibitor, reduces level of a bone 
      resorption marker in postmenopausal women with rheumatoid arthritis.
PG  - 44-9
LID - 10.1111/1756-185X.12076 [doi]
AB  - AIM: Celecoxib (CEL), a selective cyclooxygenase-2 (COX-2) inhibitor, has been 
      reported to suppress osteoclastogenesis in vitro, reduce levels of bone 
      resorption markers in ovariectomized (OVX) mice, and prevent bone destruction in 
      rheumatoid arthritis (RA) model mice; however, no clinical data has been 
      reported. Here, we prospectively evaluated the changes in bone turnover markers 
      in RA patients who switched from nonsteroidal anti-inflammatory drugs (NSAIDs) to 
      CEL, to examine the effects of selective COX-2 inhibitor on bone metabolism. 
      METHODS: RA patients who had been treated with NSAIDs for more than 12 weeks were 
      switched to CEL (400 mg/day) without any other changes in previously prescribed 
      medications. Urinary type I collagen cross-linked N-telopeptide (uNTX), serum 
      bone alkaline phosphatase (BAP), C-reactive protein (CRP), erythrocyte 
      sedimentation rate (ESR) and matrix metalloproteinase-3 (MMP-3) were evaluated 
      before switching to CEL and 16 weeks later. RESULTS: Significant reductions in 
      uNTX, a bone resorption marker, were observed in 60 female patients (P = 0.042), 
      especially in 52 postmenopausal women (P = 0.033). However, uNTX level did not 
      significantly change in premenopausal women or in men. There were no significant 
      changes in BAP, a bone formation marker. CRP significantly decreased (P = 0.007), 
      while ESR and MMP-3 were unchanged. CONCLUSION: CEL reduced the levels of a bone 
      resorption marker in postmenopausal RA patients, suggesting that this drug may 
      attenuate the accelerated osteoclastic bone resorption associated with menopause.
CI  - (c) 2013 Asia Pacific League of Associations for Rheumatology and Wiley Publishing 
      Asia Pty Ltd.
FAU - Tsuji, Shigeyoshi
AU  - Tsuji S
AD  - Department of Orthopaedic Surgery, Hoshigaoka Koseinenkin Hospital, Osaka, Japan.
FAU - Tomita, Tetsuya
AU  - Tomita T
FAU - Nakase, Takanobu
AU  - Nakase T
FAU - Hamada, Masayuki
AU  - Hamada M
FAU - Kawai, Hideo
AU  - Kawai H
FAU - Yoshikawa, Hideki
AU  - Yoshikawa H
LA  - eng
PT  - Journal Article
DEP - 20130523
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Biomarkers)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Pyrazoles)
RN  - 0 (Sulfonamides)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Aged
MH  - Arthritis, Rheumatoid/diagnosis/*drug therapy/metabolism/physiopathology
MH  - Biomarkers/blood/urine
MH  - Bone Resorption/metabolism/physiopathology/*prevention & control
MH  - Celecoxib
MH  - Cyclooxygenase 2 Inhibitors/*therapeutic use
MH  - Drug Substitution
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Postmenopause
MH  - Prospective Studies
MH  - Pyrazoles/*therapeutic use
MH  - Sulfonamides/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - C-reactive protein (CRP)
OT  - cyclooxygenase-2 (COX-2) inhibitors
OT  - postmenopause
OT  - rheumatoid arthritis (RA)
OT  - urinary type I collagen cross-linked N-telopeptide (uNTX)
EDAT- 2014/01/30 06:00
MHDA- 2014/09/30 06:00
CRDT- 2014/01/30 06:00
PHST- 2014/01/30 06:00 [entrez]
PHST- 2014/01/30 06:00 [pubmed]
PHST- 2014/09/30 06:00 [medline]
AID - 10.1111/1756-185X.12076 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2014 Jan;17(1):44-9. doi: 10.1111/1756-185X.12076. Epub 2013 May 
      23.